NasdaqCM - Nasdaq Real Time Price USD

Sonnet BioTherapeutics Holdings, Inc. (SONN)

1.7200 -0.0900 (-4.97%)
As of 10:37 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Pankaj Mohan Ph.D. Founder, Chairman, CEO & President 927k -- 1965
Dr. John K. Cini Ph.D. Chief Scientific Officer & Co-Founder 602.48k -- 1953
Mr. Jay Cross Chief Financial Officer 603.42k -- 1970
Mr. Donald J. Griffith CPA, CPA Controller & Director 134.05k -- 1949
Ms. Susan Dexter Chief Technical Officer -- -- 1955
Dr. Richard T. Kenney FACP, M.D. Chief Medical Officer -- -- 1958
Mr. Manuel Dafonseca Head of Clinical Operations -- -- --

Sonnet BioTherapeutics Holdings, Inc.

100 Overlook Center
Suite 102
Princeton, NJ 08540
United States
609 375 2227 https://www.sonnetbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
12

Description

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.

Corporate Governance

Sonnet BioTherapeutics Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 08, 2024 - May 13, 2024
Sonnet BioTherapeutics Holdings, Inc. Earnings Call

Related Tickers

HOTH Hoth Therapeutics, Inc.
1.1599
-0.86%
 
NRBO NeuroBo Pharmaceuticals, Inc.
3.1500
+1.61%
 
ADTX Aditxt, Inc.
2.4150
+1.90%
 
DRUG Bright Minds Biosciences Inc.
1.0919
+0.17%
 
VCNX Vaccinex, Inc.
5.47
+9.40%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.6350
-1.17%
 
XBIO Xenetic Biosciences, Inc.
3.7700
-0.26%
 
KPRX Kiora Pharmaceuticals, Inc.
0.4935
-2.43%
 
VRPX Virpax Pharmaceuticals, Inc.
2.8600
-7.44%
 
TENX Tenax Therapeutics, Inc.
3.5450
-0.42%